Nexium Buyers Defend New Trial Bid In Pay-For-Delay Suit
Walgreen, CVS and other Nexium buyers pushed the First Circuit again Wednesday to reverse a district court's ruling dismissing their claims that AstraZeneca's Hatch Waxman Act settlement with Ranbaxy harmed competition...To view the full article, register now.
Already a subscriber? Click here to view full article